Predictive oncology inc.'s wholly owned subsidiary, tumorgenesis, partners with cellevate ab

Minneapolis, may 20, 2021 (globe newswire) -- predictive oncology (nasdaq: poai), an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary, tumorgenesis (tumorgenesis.net), has partnered a deal with the swedish firm cellevate ab (cellevate.com). the companies are combining tumorgenesis' medias with cellevate's high engineered matrix materials. this partnering opens new territories for both companies.
POAI Ratings Summary
POAI Quant Ranking